somatrogon · NGENLA

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Growth Hormone Deficiency

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
EU
  • Long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone
Product first approved 2022EMA
JP
  • Treatment of short stature due to growth hormone deficiency prior to epiphyseal closure
Product first approved 2022PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Growth Hormone Deficiency
Other / comorbidity
NCT07226089 · Rabin Medical Center
2026-02-01 – 2028-01 · ISS, SGA
What this study did
Phase 1 (1)
Other / comorbidity
NCT03810664 · OPKO Health, Inc.
2019-01-18 – 2019-04-19 · Healthy Male Volunteers
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Growth Hormone Deficiency: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Somatrogon (NGENLA): this drugApprovedProtein / enzyme therapeuticGrowth hormone receptorPartial signal
NCT03831880: Overall life interference total score (DCOA 1), crossover: weekly somatrogon 8.63 vs daily Genotropin 24.13; difference -15.49 (95% CI -19.71 to -11.27), p<0.0001 (CT.gov posted results).
Lonapegsomatropin (Skytrofa)ApprovedProtein / enzyme therapeuticGrowth hormone receptorPartial signalFeatured results are safety and non-efficacy only in this race
Somatropin (Serostim)
Approved(overall)
Protein / enzyme therapeuticGrowth hormone receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Somatropin (Jintropin)
Phase 3(overall)
Biologic (subtype unspecified)Growth hormone receptor
Partial signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow NGENLA (somatrogon) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 3ISS, SGARecruiting
Est. primary completion 2027-12 · NCT07226089 · CT.gov ↗
What to watch

See the full readout calendar ↗